Seyed Nasser Ostad
Department of Toxicology and Pharmacology, Tehran University of Medical Sciences, P.O. Box 14155/6451 Tehran, Iran
Mohsen Amini
Department of Medicinal Chemistry, Faculty of Pharmacy, Pharmaceutical Sciences Research Center,
Tehran University of Medical Sciences, P.O. Box 14155/6451 Tehran, Iran
Zahra Haghipour
Department of Toxicology and Pharmacology, Tehran University of Medical Sciences, P.O. Box 14155/6451 Tehran, Iran
Leila Karimi
Department of Medicinal Chemistry, Faculty of Pharmacy, Pharmaceutical Sciences Research Center,
Tehran University of Medical Sciences, P.O. Box 14155/6451 Tehran, Iran
Latifeh Navidpour
Department of Medicinal Chemistry, Faculty of Pharmacy, Pharmaceutical Sciences Research Center,
Tehran University of Medical Sciences, P.O. Box 14155/6451 Tehran, Iran
ABSTRACT
Recent studies have suggested cyclooxygenase-2 (COX-2) expression as a mechanism involved in carcinogenesis. It has also been suggested that changes in COX-2 expression level can be considered as a possible therapeutic target in tumors. Therefore, it was decided to synthesize a new series of 4, 5-diaryl thiadiazoles (compounds 1-5) as COX-2 inhibitors and evaluate their inhibitory activity on COX-2 expression. The COX-2 expression was induced by lipopolysaccharide (LPS) in bovine aortic endothelial (BAE-1) cells and the protein expression was evaluated by immunocytochemistry (ICC). The inhibitory activity of these compounds has been compared with celecoxib and rofecoxib as selective COX-2 inhibitors and indomethacin as a non-selective COX inhibitor. The cytotoxicity of these compounds was measured in different concentrations (10-3 -103 μg mL-1 ) by trypan blue dye exclusion method. The results showed that the cell viability following exposure to 10-2 μg mL-1 of each one of compounds 1-4 was about 90%. Among all tested compounds, compound 4 at 10-2 μg mL-1 showed significant inhibition on COX-2 expression determined by ICC. This effect of compound 4 was comparable to rofecoxib and celecoxib. It is concluded that, the new synthesized compounds and in particular, the compound 4 can be considered for further evaluation as new COX-2 inhibitors.
PDF References
How to cite this article
Seyed Nasser Ostad, Mohsen Amini, Zahra Haghipour, Leila Karimi and Latifeh Navidpour, 2005. Inhibitory Activities of New Series of 4, 5-diaryl Thiadiazoles Derivatives on
Lipopolysaccharide-induced Cox-2 Expression. International Journal of Pharmacology, 1: 79-84.
DOI: 10.3923/ijp.2005.79.84
URL: https://scialert.net/abstract/?doi=ijp.2005.79.84
DOI: 10.3923/ijp.2005.79.84
URL: https://scialert.net/abstract/?doi=ijp.2005.79.84
REFERENCES
- Kurumbail, R.G., A.M. Stevens, J.K. Gierse, J.J. McDonald and R.A. Stegenman et al., 1996. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384: 644-648.
PubMedDirect Link - Wong, E., C. Deluca, C. Boily, S. Charleson, W. Cromlish and D. Denis, 1997. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflammat. Res., 46: 51-59.
CrossRefDirect Link - Cianch, F., C. Cortesini, P. Bechi, O. Fantappie, L. Messerini and A. Vannacci, 2001. Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology, 121: 1339-1347.
PubMedDirect Link - Gauthier, J.Y., Y. Leblanc, W.C. Black, C. Chan, W.A. Cromlish and R. Gordon, 1996. Synthesis and biological evaluation of 2, 3-diarylthiopen as selective COX-2 inhibitors. PART II: Replacing the heterocycle. Synthesis and biological evaluation of 2, 3-diarylthiopen as selective COX-2 inhibitors. Med. Chem. Lett, 6: 87-92.
- Fredika, M., M.L. Robertson, F.S. Parrett, M.R. Joarder, M.A.I. Hussein, A. Galal and E.H. Randall, 1998. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinoma. Cancer Lett., 122: 165-175.
PubMedDirect Link - Akarasereenont, P., J.A. Mitchell, Y.S. Bakhle, C. Thiemermann and J.R. Vane, 1995. Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur. J. Pharmacol., 273: 121-128.
Direct Link - Choi, H.B., C. Khoo, J.K. Ryu, E.V. Breemen, S.U. Kim and J.G. McLarnon, 2002. Inhibition of lipopolysaccaride-induced cyclooxygenase-2, tumor necrosis factor-α and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195. J. Neurochem., 83: 546-555.
Direct Link - Antoniotti, S., D. Lovisolo, A.F. Pla and L. Munaron, 2002. Expression and functional role of bTRPC1 channels in native endothelial cells. FEBS Lett., 510: 189-195.
PubMedDirect Link - Araki, E., C. Forster, J.M. Dubinsky, M.E. Ross and C. Iadecola, 2001. Cyclooxygenase-2 inhibitor NS-398 protects neuronal cultures from lipopolysaccaride-induced neurotoxicity. Stroke, 32: 2370-2375.
PubMedDirect Link - Bany, B.M. and T.G. Kennedy, 1997. Regulation of cyclooxygenase gene expression in rat endometrial stromal cells: The role of epidermal growth factor. Dev. Genet., 21: 109-115.
PubMedDirect Link